虎踞乙肝胶囊联合阿德福韦酯抗慢性乙肝肝纤维化的疗效观察

    Efficacy observation of Hujuyigan capsule against liver fibrosis in chronic hepatitis B

    • 摘要: 目的:观测阿德福韦酯(ADV)与虎踞乙肝胶囊联合治疗慢性乙型肝炎(CHB)肝纤维化的疗效。方法:选择65例CHB病人,按数字奇偶法将其分为观察组和对照组,对照组口服ADV 10 mg,每天1次,观察组在对照组治疗的基础上加服虎踞乙肝胶囊1 g,每天3次。2组均用药6个月。观察治疗前后2组病人的丙氨酸氨基转移酶复常率、乙型肝炎病毒e抗原转阴率、HBV DNA转阴率、肝纤维化指标及免疫功能的变化。结果:治疗6个月后,2组病人丙氨酸氨基转移酶复常率、乙型肝炎病毒e抗原转阴率和HBV DNA转阴率差异均无统计学意义(P>0.05)。观察组的肝纤维化指标均较对照组下降更明显(P<0.01)。与对照组比较,观察组γ-干扰素的表达出现了明显的上调,抑制了肿瘤坏死因子-α和白细胞介素-4的表达(P<0.01)。结论:虎踞乙肝胶囊联合ADV治疗CHB有显著疗效,适于在临床推广、应用。

       

      Abstract: Objective:To investigate the effects of adefovir dipivoxil(ADV) combined with Hujuyigan capsule in the treatment of liver fibrosis in chronic hepatitis B(CHB).Methods:Sixty-five CHB patients were divided into the observation group and control group according to the number of parity.The control group were treated with ADV by oral,and the observation group were additionally treated with Hujuyigan capsule based on the control group.The ALT recovery rate,HBeAg and HBV DNA converting negative rates,hepatic fibrosis indexes and immune function in two groups were observed before and after treatment.Results:Six months after treatment,the differences of the ALT recovery rate,and HBeAg and HBV DNA converting negative rates between two groups were not statistically significant(P>0.05).Compared with the control group,the hepatic fibrosis indexes in observation group significantly decreased(P<0.01).Compared with the control group,the expression of Ⅰ γ interferon in observation group was obviously up-regulated,and the expressions of tumor necrosis factor α and interleukin-4 were inhibited(P<0.01).Conclusions:The curative efficacy of Hujuyigan capsule and ADV in treating CHB is significant,which is worthy of popularization and application.

       

    /

    返回文章
    返回